Compare Ford Motor Company (F) vs Nuvalent Inc (NUVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ford Motor Company vs Nuvalent Inc — how do they compare? Ford Motor Company trades at $14.19 (market cap $56.50B), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Ford Motor Company is far larger — about 5.8× Nuvalent Inc's market cap, and Ford Motor Company pays a 4.23% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.
| F | NUVL | |
|---|---|---|
Market Cap | $56.50B | $9.81B |
Sector | Consumer Cyclical | Technology |
52-Week High | $17.44 | $123.96 |
52-Week Low | $10.82 | $72.16 |
Enterprise Value | $185.53B | $8.52B |
Dividend Yield | 4.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ford (F) trades at $13.93, up 0.44% on the day, with a neutral technical outlook and mixed fundamental signals. The company reported a net loss of $8.18 billion in 2025 despite revenue growth to $187.27 billion, reflecting margin pressure. Recent news highlights labor agreements, EV initiatives, and a 4%+ dividend yield. Analyst consensus is a $15.00 price target with a Hold-heavy rating distribution.
The stock presents a value opportunity with low P/E and P/S ratios, but significant risks include persistent net losses, high debt levels, and competitive pressures in the EV transition. Upside depends on execution of cost controls and successful new product launches, particularly in electric vehicles.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ford Motor Company
Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →
